Nephrotic proteinuria is the hallmark of several glomerulonephritis determined by different
pathogenetic mechanisms, including autoimmune, degenerative and inflammatory. Some …

The administration of T cells that have been modified to carry chimeric antigen receptors
(CARs) aimed at B cells has been an effective strategy in treating B cell malignancies. This …

Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies
against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin …

Background The chimeric anti-CD20 monoclonal antibody rituximab is effective in steroid-
dependent and calcineurin inhibitor–dependent forms of nephrotic syndrome, but many …

It is now two decades since Rituximab was first used in the treatment of patients with
systemic lupus erythematosus. There have been many challenges but in spite of failing to …

Infusion of T cells engineered to express chimeric antigen receptors (CARs) that target B
cells has proven to be a successful treatment for B cell malignancies. This success inspired …

In this study we show that glycosylation is relevant for immune recognition of therapeutic
antibodies, and that defined glycan structures can modulate immunogenicity. Concerns …

Objectives High rates of anti-drug antibodies (ADA) to rituximab have been demonstrated in
patients undergoing treatment for SLE. However, little is known with regard to their long-term …

Objectives The frequency and consequences of anti-drug antibodies to rituximab (RTX-ADA)
are not well known in RA and even less in other systemic auto-immune diseases (sAID). We …

Background Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained
remission in children with steroid-dependent nephrotic syndrome. However, there is no …